REG - OptiBiotix Health - Commercial agreement signed with KSF Acquisition <Origin Href="QuoteRef">OPTIO.L</Origin>

OptiBiotix HealthAnnouncement

13/01/2016 07:10

RNS Number : 6516L
OptiBiotix Health PLC
13 January 2016
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Commercial Agreement signed withKSF Acquisition UK Limited
OptiBiotixHealthplc(AIM: OPTI),alifesciencesbusinessdevelopingproducts totackleobesity,high cholesterol anddiabetes, announcesthatithas entered into a commercial agreement with KSF AcquisitionUK Limited ('KSF). The agreement provides funding to assess the benefits of using Optibiotix's SlimBiome weight management product alongside KSF's weight management dietary programme and provides KSF with an option to commercialise SlimBiome.
OptiBiotix's SlimBiomecontains ingredients clinically proven to reduce weight formulated by world experts to act at different parts of the body in three different ways to affect appetite, metabolism, and energy harvest.
KSF's established brand with its scientifically proven weight management programme uses meal replacement products to support weight loss.
StephenO'Hara,CEOofOptiBiotix,commented:"We are pleased to announce the signing of this commercial agreement with KSF, whose dietary programme is a trusted and well recognised global brand in weight management. This agreement brings together OptiBiotix's novel science with KSF's industry expertise, product range, and market reach to access a market estimated globally to be worth $622bn in 2015. OptiBiotix continues to make strong commercial progress across all it platforms consistent with its strategy of creating multiple product and partnering opportunities for large global markets with an unmet need."
OptiBiotix Health plc
www.optibiotix.com
Stephen O'Hara, Chief Executive
Contact via Walbrook below


Cairn Financial Advisers LLP
Tel: 020 7148 7900
Liam Murray / Avi Robinson



Hybridan LLP (Joint Broker)
Tel: 020 3764 2341
Claire Louise Noyce

Peterhouse Corporate Finance Ltd (Joint Broker)
Tel: 020 7469 0936
Lucy Williams / Duncan Vasey



Walbrook PR Ltd
Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy
Mob: 07876 741 001
Mike Wort
Mob: 07900 608 002


About OptiBiotix Health PLC - www.optibiotix.com 
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease. 
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes. 
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen and OptiBiotic platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases. 
About KSF ACQUISITION UK LIMITED (KSF) www.slimfast.co.uk
KSF Acquisition UK Ltd. is an investee of Kainos Capital, with a responsibility for the SlimFast brand in the UK, Ireland and Germany. Kainos Capital acquired the SlimFast brand from Unilever in 2014. SlimFast is a scientifically proven weight loss plan with a branded range of shakes, bars and snacks.The global market for slimming and dietary products is estimated at $622bn.

This information is provided by RNS
The company news service from the London Stock Exchange
  END
AGRQLLFFQFFZBBV